Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in JAMA Oncol

Retrieve available abstracts of 64 articles:
HTML format



Single Articles


    November 2022
  1. DESAI AP, Adashek JJ, Reuss JE, West HJ, et al
    Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2022 Nov 17. pii: 2798846. doi: 10.1001/jamaoncol.2022.5389.
    PubMed     Abstract available


  2. KATZ MS, Russo GA
    Defining a Therapeutic Ratio for Stereotactic Ablative Radiation Therapy in Oligometastatic Disease-Another Piece of the Puzzle.
    JAMA Oncol. 2022;8:1650-1651.
    PubMed    


  3. OLSON R, Jiang W, Liu M, Bergman A, et al
    Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    JAMA Oncol. 2022;8:1644-1650.
    PubMed     Abstract available


  4. STROHBEHN GW, Holleman R, Burns J, Klamerus ML, et al
    Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
    JAMA Oncol. 2022;8:1663-1667.
    PubMed     Abstract available


    October 2022
  5. CANOVA S, Arcangeli S, Cortinovis DL
    A Cast of Shadow on Postoperative Radiotherapy for pIIIA-N2 Non-Small Cell Lung Cancer?
    JAMA Oncol. 2022 Oct 13. pii: 2797485. doi: 10.1001/jamaoncol.2022.4442.
    PubMed    


  6. MORIZANE C, Machida N, Honma Y, Okusaka T, et al
    Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:1447-1455.
    PubMed     Abstract available


    September 2022
  7. KIM KH, Oh J, Yang G, Lee J, et al
    Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer.
    JAMA Oncol. 2022 Sep 22. pii: 2796765. doi: 10.1001/jamaoncol.2022.4202.
    PubMed     Abstract available


  8. VOLK RJ, Stacey D
    Ensuring High-Quality Shared Decision-making for Lung Cancer Screening.
    JAMA Oncol. 2022 Sep 8. pii: 2796098. doi: 10.1001/jamaoncol.2022.3766.
    PubMed    


  9. GERBER DE, Singh H, Larkins E, Ferris A, et al
    A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
    JAMA Oncol. 2022;8:1333-1339.
    PubMed     Abstract available


    August 2022
  10. RICCIUTI B, Wang X, Alessi JV, Rizvi H, et al
    Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    JAMA Oncol. 2022;8:1160-1168.
    PubMed     Abstract available


    July 2022
  11. DESAI A, Velazquez AI, West HJ
    Perioperative Therapy in Early-Stage Lung Cancer.
    JAMA Oncol. 2022 Jul 28. pii: 2794804. doi: 10.1001/jamaoncol.2022.1940.
    PubMed    


  12. FASELIS C, Nations JA, Morgan CJ, Antevil J, et al
    Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended.
    JAMA Oncol. 2022 Jul 28. pii: 2794805. doi: 10.1001/jamaoncol.2022.2952.
    PubMed     Abstract available


  13. XU J, Liu Z, Bai H, Dong G, et al
    Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2022 Jul 21. pii: 2794634. doi: 10.1001/jamaoncol.2022.2719.
    PubMed     Abstract available


    April 2022
  14. LOUIE AV, Granton PV, Fairchild A, Bezjak A, et al
    Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:1-7.
    PubMed     Abstract available


    March 2022
  15. KEHL KL, Zahrieh D, Yang P, Hillman SL, et al
    Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
    JAMA Oncol. 2022 Mar 17. pii: 2790373. doi: 10.1001/jamaoncol.2022.0039.
    PubMed     Abstract available


  16. ARRIETA O, Zatarain-Barron ZL, Turcott JG, Barron F, et al
    Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:477-479.
    PubMed    


    February 2022
  17. ROBBINS HA, Landy R, Ahluwalia JS
    Achieving Equity in Lung Cancer Screening for Black Individuals Requires Innovation to Move Beyond "Equal" Guidelines.
    JAMA Oncol. 2022 Feb 24. pii: 2789385. doi: 10.1001/jamaoncol.2021.7252.
    PubMed    


  18. ZHAO B, Ma W
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    JAMA Oncol. 2022 Feb 10. pii: 2789076. doi: 10.1001/jamaoncol.2021.7784.
    PubMed    


  19. GIL-SIERRA MD, Del Pilar Briceno-Casado M, Sanchez-Hidalgo M
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    JAMA Oncol. 2022 Feb 10. pii: 2789075. doi: 10.1001/jamaoncol.2021.7787.
    PubMed    


  20. GETTINGER S, Redman MW, Herbst RS
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply.
    JAMA Oncol. 2022 Feb 10. pii: 2789074. doi: 10.1001/jamaoncol.2021.7790.
    PubMed    


  21. HE MM, Lo CH, Wang K, Polychronidis G, et al
    Immune-Mediated Diseases Associated With Cancer Risks.
    JAMA Oncol. 2022;8:209-219.
    PubMed     Abstract available


  22. BROWN S, Lavery JA, Shen R, Martin AS, et al
    Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.
    JAMA Oncol. 2022;8:287-291.
    PubMed     Abstract available


    January 2022
  23. ZHANG-VELTEN E, Iyengar P, Timmerman RD
    Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?-Reply.
    JAMA Oncol. 2022 Jan 13. pii: 2788056. doi: 10.1001/jamaoncol.2021.7160.
    PubMed    


  24. OHRI N, Werner-Wasik M
    Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?
    JAMA Oncol. 2022 Jan 13. pii: 2788057. doi: 10.1001/jamaoncol.2021.7157.
    PubMed    


  25. PU CY, Lusk CM, Neslund-Dudas C, Gadgeel S, et al
    Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    JAMA Oncol. 2022 Jan 13. pii: 2788055. doi: 10.1001/jamaoncol.2021.6720.
    PubMed     Abstract available


  26. NITZ JA, Erkmen CP
    New 2021 USPSTF Lung Cancer Screening Criteria-An Opportunity to Mitigate Racial Disparity.
    JAMA Oncol. 2022 Jan 13. pii: 2788059. doi: 10.1001/jamaoncol.2021.6708.
    PubMed    


    December 2021
  27. NEBHAN CA, Cortellini A, Ma W, Ganta T, et al
    Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
    JAMA Oncol. 2021;7:1856-1861.
    PubMed     Abstract available


    November 2021
  28. POTTER AL, Yang CJ, Woolpert KM, Puttaraju T, et al
    Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines.
    JAMA Oncol. 2021 Nov 24. pii: 2786539. doi: 10.1001/jamaoncol.2021.5790.
    PubMed    


  29. KAPOOR A, Prabhash K
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Nov 4. pii: 2785696. doi: 10.1001/jamaoncol.2021.5608.
    PubMed    


  30. TIAN L, Huang B, Wei LJ
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Nov 4. pii: 2785697. doi: 10.1001/jamaoncol.2021.5605.
    PubMed    


  31. JABBOUR SK, Keller SM, Reck M
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2021 Nov 4. pii: 2785695. doi: 10.1001/jamaoncol.2021.5611.
    PubMed    


    October 2021
  32. SINGH H, Beaver JA, Pazdur R
    Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 Losses.
    JAMA Oncol. 2021 Oct 28. pii: 2785674. doi: 10.1001/jamaoncol.2021.4956.
    PubMed    


  33. MULSHINE JL, Pyenson B
    The Long, Slow Road to Lung Cancer Cure.
    JAMA Oncol. 2021 Oct 21. pii: 2784991. doi: 10.1001/jamaoncol.2021.4711.
    PubMed    


  34. GANTI AK, Klein AB, Cotarla I, Seal B, et al
    Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
    JAMA Oncol. 2021 Oct 21. pii: 2784988. doi: 10.1001/jamaoncol.2021.4932.
    PubMed     Abstract available


  35. TOUMAZIS I, de Nijs K, Cao P, Bastani M, et al
    Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
    JAMA Oncol. 2021 Oct 21. pii: 2784987. doi: 10.1001/jamaoncol.2021.4942.
    PubMed     Abstract available


  36. ZHOU C, Ramalingam SS, Kim TM, Kim SW, et al
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Oct 14:e214761. doi: 10.1001/jamaoncol.2021.4761.
    PubMed     Abstract available


  37. AMINI A
    Managing Pulmonary Oligometastatic Disease With Stereotactic Body Radiation Therapy-Moving the Field Forward 1 Organ at a Time.
    JAMA Oncol. 2021;7:1485-1486.
    PubMed    


  38. HUANG S, Gao Z, Qiao G
    Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers.
    JAMA Oncol. 2021;7:1580.
    PubMed    


  39. WANG J, Leaw SJ, Lu S
    Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers-Reply.
    JAMA Oncol. 2021;7:1580-1581.
    PubMed    


    September 2021
  40. DAGOGO-JACK I
    Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench.
    JAMA Oncol. 2021 Sep 2. pii: 2783495. doi: 10.1001/jamaoncol.2021.3369.
    PubMed    


  41. HORN L, Wang Z, Wu G, Poddubskaya E, et al
    Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2021 Sep 2. pii: 2783490. doi: 10.1001/jamaoncol.2021.3523.
    PubMed     Abstract available


    August 2021
  42. KHANDEKAR MJ, Keane FK
    Radiation Dose and Fractionation in Locally Advanced Lung Cancer: A Simple Question With a Complicated Answer.
    JAMA Oncol. 2021 Aug 12. pii: 2783009. doi: 10.1001/jamaoncol.2021.3180.
    PubMed    


  43. IYENGAR P, Zhang-Velten E, Court L, Westover K, et al
    Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
    JAMA Oncol. 2021 Aug 12. pii: 2783004. doi: 10.1001/jamaoncol.2021.3186.
    PubMed     Abstract available


    July 2021
  44. EZE C, Belka C, Manapov F
    Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Jul 29. pii: 2782115. doi: 10.1001/jamaoncol.2021.2316.
    PubMed    


  45. TSAKIRIDIS T, Pond GR, Wright J, Ellis PM, et al
    Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 29. pii: 2782110. doi: 10.1001/jamaoncol.2021.2328.
    PubMed     Abstract available


  46. SKINNER H, Hu C, Tsakiridis T, Santana-Davila R, et al
    Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 29. pii: 2782111. doi: 10.1001/jamaoncol.2021.2318.
    PubMed     Abstract available


  47. GETTINGER SN, Redman MW, Bazhenova L, Hirsch FR, et al
    Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 15. pii: 2781889. doi: 10.1001/jamaoncol.2021.2209.
    PubMed     Abstract available


  48. HUANG H, Feng YL, Liu JH
    Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer-Reply.
    JAMA Oncol. 2021 Jul 15. pii: 2781892. doi: 10.1001/jamaoncol.2021.2113.
    PubMed    


  49. SARI SY, Kahvecioglu A, Yildiz F
    Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer.
    JAMA Oncol. 2021 Jul 15. pii: 2781893. doi: 10.1001/jamaoncol.2021.2110.
    PubMed    


  50. BARTELS F, Wandrey MM, Aigner A, Stronisch T, et al
    Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer.
    JAMA Oncol. 2021 Jul 1. pii: 2781389. doi: 10.1001/jamaoncol.2021.2049.
    PubMed     Abstract available


  51. JACOBSON JO
    Accompanying Patients in the Time of COVID-19.
    JAMA Oncol. 2021;7:971-972.
    PubMed    


    June 2021
  52. HUI Z, Men Y, Hu C, Kang J, et al
    Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
    JAMA Oncol. 2021 Jun 24. pii: 2781087. doi: 10.1001/jamaoncol.2021.1910.
    PubMed     Abstract available


  53. JABBOUR SK, Lee KH, Frost N, Breder V, et al
    Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
    JAMA Oncol. 2021 Jun 4. pii: 2780855. doi: 10.1001/jamaoncol.2021.2301.
    PubMed     Abstract available


  54. TAKSLER GB, Peterse EFP, Willems I, Ten Haaf K, et al
    Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
    JAMA Oncol. 2021;7:885-894.
    PubMed     Abstract available


  55. CHMURA S, Winter KA, Robinson C, Pisansky TM, et al
    Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
    JAMA Oncol. 2021;7:845-852.
    PubMed     Abstract available


    May 2021
  56. CORBETT K, Sharma A, Pond GR, Brastianos PK, et al
    Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
    JAMA Oncol. 2021 May 20. pii: 2780060. doi: 10.1001/jamaoncol.2021.1359.
    PubMed    


  57. DEL PAGGIO JC, Berry JS, Hopman WM, Eisenhauer EA, et al
    Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
    JAMA Oncol. 2021;7:728-734.
    PubMed     Abstract available


  58. HOROWITZ DP, Goodman K, Kachnic LA
    Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer-Ready for Prime Time?
    JAMA Oncol. 2021;7:687-688.
    PubMed    


  59. STELWAGEN J, de Vries EGE, Walenkamp AME
    Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review.
    JAMA Oncol. 2021;7:759-770.
    PubMed     Abstract available


    April 2021
  60. SUN L, Tan M, Cohen RB, Langer CJ, et al
    Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
    JAMA Oncol. 2021 Apr 15. pii: 2778198. doi: 10.1001/jamaoncol.2021.0546.
    PubMed    


  61. KAMRAN SC, Yeap BY, Ulysse CA, Cronin C, et al
    Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Apr 8. pii: 2778095. doi: 10.1001/jamaoncol.2021.0281.
    PubMed     Abstract available


  62. SHITARA K, Tabernero J
    Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-Reply.
    JAMA Oncol. 2021;7:633.
    PubMed    


  63. MCCAW ZR, Ludmir EB, Wei LJ
    Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer.
    JAMA Oncol. 2021;7:632-633.
    PubMed    


    January 2021
  64. CHU CY, Er HP, Lin CC
    Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy.
    JAMA Oncol. 2021;7:124-125.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: